# Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/considerations-in-demonstrating-interchangeability-with-a-reference-product-guidance-for-industry/3c6c8653-5a0c-4cb1-b776-530e73843765

> FDA guidance document: Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry. Issue date: May 14, 2019. Get complete insights and analysis.

---

## Details

- Title: Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-05-14
- Last Changed: 2024-06-20
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-D-0154">FDA-2017-D-0154</a>

## Related Documents

- [Referencing Approved Drug Products in ANDA Submissions Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/referencing-approved-drug-products-in-anda-submissions-guidance-for-industry/a3f26b8f-0c5a-443b-b665-6fef99ae7de4)
- [Scientific Considerations in Demonstrating Biosimilarity to a Reference Product](https://www.globalkeysolutions.net/guidances/guidance-document/scientific-considerations-in-demonstrating-biosimilarity-to-a-reference-product/b98b0335-f4b7-4a14-88b1-7ea4d02c7e37)
- [Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/adaptive-design-clinical-trials-for-drugs-and-biologics-guidance-for-industry/97c6b6e1-4164-4fbe-8059-b0aa3fd39415)